| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563165 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Nov, 2013
(10 years ago) | |
| US5466823 | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
Nov, 2013
(10 years ago) | |
|
US5466823 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
May, 2014
(9 years ago) | |
|
US5563165 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
May, 2014
(9 years ago) | |
| US5760068 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Jun, 2015
(8 years ago) | |
| USRE44048 | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Jun, 2015
(8 years ago) | |
|
US5760068 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Dec, 2015
(8 years ago) | |
|
USRE44048 (Pediatric) | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Dec, 2015
(8 years ago) | |
Celebrex is owned by Upjohn.
Celebrex contains Celecoxib.
Celebrex has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Celebrex are:
- US5563165
- US5466823
- US5466823*PED
- US5563165*PED
- US5760068
- USRE44048
- US5760068*PED
- USRE44048*PED
Celebrex was authorised for market use on 15 December, 2006.
Celebrex is available in capsule;oral dosage forms.
Celebrex can be used as treatment of osteoarthritis, treatment of inflammation or an inflammation-associated disorder.
The generics of Celebrex are possible to be released after 02 December, 2015.
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 15 December, 2006
Treatment: Treatment of inflammation or an inflammation-associated disorder; Treatment of osteoarthritis
Dosage: CAPSULE;ORAL
CELEBREX family patents
